Abstract: ［Abstract］ Objective〖HTSS〗〓To explore the efficacy and safety of alogliptin, acarbose and repaglinide in patients with type 2 diabetic mild cognitive impairment inadequately controlled by metformin.
〖HTH〗〖WTHZ〗Methods〖HTSS〗〓The 120 patients with type 2 diabetic mild cognitive impairment inadequately controlled by metformin were randomly divided into thealogliptin group(n=40), theacarbose group(n=40) and therepaglinidegroup(n=40). During the 22week treatment period, patients in the alogliptin group were given metformin and alogliptin, patients in the acarbose group were given metformin and acarbose and patients in the repaglinide group were given metformin and repaglinide. At week 0, 12 and 24 of the clinic trial, hemoglobin A1c(HbA1c), fasting plasma glucose(FPG), 2 h postprandial blood glucose(2 hPBG), triglycerides(TG), total cholesterol(TC) were measured, all hypoglycemic events and gastrointestinal reaction during the trial recorded and the percentage of patients achieving HbA1c target of <7% were recorded.
〖HTH〗〖WTHZ〗Results〖HTSS〗〓After the treatment, HbA1c, FPG and 2 hPBG in three groups lowered obviously. Comparing with those before treatment, the differences were significant(P＜001), while there were no significant changes among the three groups in TG and TC（P＞005）. There were no significant difference among the three groups in HbA1c, FPG, 2 hPBG , TG and TC（P＞005）. After the treatment, the percentage of patients achieving HbA1c target of <7% was highest(74.36%, χ2=6.496， P＜001),  the incidence of hypoglycemia(2.56%， χ2=16.955， P＜001) and gastrointestinal reaction(0.00%, χ2=37.853， P＜001) in the alogliptin group was lowest  among the three groups.
〖HTH〗〖WTHZ〗Conclusion〖HTSS〗〓The efficacy of alogliptin was not inferior to that of acarbose and regrainidein patients with type 2 diabetic mild cognitive impairment inadequately controlled by metformin, while compared with them, the incidences of hypoglycemia and gastrointestinal reaction were lowest in those treated by alogliptin.

Key words: diabetes mellitus, type 2, mild cognitive impairment, alogliptin